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Abstract
Cancer is universally considered a disease of ageing. Today the management of elderly cancer
patients poses many specific problems and it should be revisited in the light of the most recent
advances in both diagnosis and treatment of human malignancies. In particular, the potential use of
novel therapeutic options, based on therapeutic agents raised against molecular targets (the so
called targeted therapy), appears to be promising in this clinical settings especially in view of the
limited side-effects. The mainstays of cancer treatment during the twentieth century were surgery,
radiation and chemotherapy. However, surgery is not curative in metastatic disease, radiation and
chemotherapy are limited by side effects because they can't discriminate between healthy and
cancerous cells. When key molecular changes responsible for malignant transformation were
identified (e.g. growth factors and their receptors), it was hoped that new targeted agents, by
inhibiting cancer-specific pathways, would spare normal cells and thereby offer improved safety
benefits and a higher therapeutic index over standard chemotherapeutics. The most common
targeted therapies used in clinical practice, i.e. monoclonal antibodies and small molecules, are
described.
Introduction: the ageing and cancer interface
Cancer is generally considered a disease of ageing,
although the shared mechanisms underpinning the two
processes remain unclear. Doubtlessly, incidence and
mortality rates of most human cancers increase consist-
ently with age, but they decline in the oldest old (≥ 90
years). This finding has been interpreted as a consequence
of either the exploitation of large-scale population screen-
ing programs or the improvement of diagnostic capacities
worldwide. However, there is convincing evidence that,
regardless of other variables, cancer and aging remain
associated until around 85 years of age, while they diverge
substantially thereafter.
Recent studies have suggested that either "convergent" or
"divergent" mechanisms may connect cancer and aging.
In the former, molecular pathways simultaneously pro-
vide protection against cancer and resistance to ageing by
limiting the generation and accumulation of cellular,
genetic or epigenetic, damage. In the latter, some other
pathways may eventually lead to protect from cancer but
also to promote ageing, including shortening of telomeres
and derepression of the INK4a/ARF locus.
It ought to be emphasized here that, by the year 2030,
most patients with cancer will be aged over 65 years and
many will be frail. Frailty implies a diminished physio-
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logic reserve; contributors include diminished organ func-
tion, co-morbidities, impaired physical function, and
geriatric syndromes. Oncologists are challenged to appro-
priately identify frail elderly cancer patients aiming to
select appropriate therapies that will minimize toxicity
and maintain quality of life. In this framework, the advent
of targeted therapies and their potential use in the elderly
clinical cancer setting is awaited with hope and growing
interest.
The mainstays of cancer treatment during the twentieth
century were surgery, radiation and chemotherapy. How-
ever, surgery is not curative in cases of metastatic disease,
and radiation and chemotherapy are limited by severe
side effects and a limited capacity to discriminate between
healthy and cancerous cells.
In the 1980s, several groups began to identify the key
molecular changes responsible for malignant transforma-
tion. These changes included the discovery of both cancer-
causing oncogenes and tumor-suppressor genes that nor-
mally hold cancer in check, and the identification of epi-
genetic events such as promoter methylation that
predispose individuals to cancer by switching genes that
regulate cell growth on or off.
Cancer cells may acquire the capacity for autonomous and
dysregulated proliferation through the uncontrolled pro-
duction of specific molecules, generally encoded by onco-
genes, that promote cell growth (growth factors) or
through abnormal, enhanced expression of specific pro-
teins (growth factor receptors) on the cell membranes to
which growth factors selectively bind. Both processes trig-
ger a series of intracellular signals that ultimately lead to
the proliferation of cancer cells, induction of angiogenesis
and metastasis. It was hoped that new targeted agents, by
inhibiting cancer-specific pathways, would spare normal
cells and thereby offer improved safety benefits over
standard chemotherapeutics, while also providing a
higher therapeutic index.
Molecular targets and specific bullets: current 
clinical use and future perspectives
The human epidermal growth factor receptor (HER) fam-
ily consists in four receptor proteins, that are transmem-
brane tyrosine kinases and bind to specific ligands: HER1
or epidermal growth factor receptor (EGFR), HER2, HER3
and HER4.
These receptors can be inhibited by either monoclonal
antibodies (e.g. trastuzumab, cetuximab), that bind to the
extracellular domain of the receptor when it is in the inac-
tive configuration, compete for the receptor binding by
occluding the ligand-binding region, and thereby block
ligand-induced receptor associated tyrosine kinase activa-
tion, or by a tyrosine kinase inhibitor or small molecule
(e.g. erlotinib, gefitinib, lapatinib), that competes with
ATP to bind to the intracellular catalytic domain of recep-
tor tyrosine kinase, thus inhibiting receptor autophospho-
rylation and downstream signaling.
HER2 normally regulates cell proliferation. Some
tumours, in particular breast tumours, overepress HER2, a
transmembrane receptor protein encoded by the proto-
oncogene HER2/neu: infact, overexpression of HER2
(excess production of protein), amplification of the gene
(excess number of copies) or both occur in approximately
20–30% of primary breast cancers, and are associated
with a clinically aggressive tumour and a poor prognosis.
Overexpression of HER2 is detected by immunohisto-
chemistry (IHC), the most frequently used method, while
the amplification of the gene in the nuclei of affected cells
can be detected using fluorescence in situ hybridization
(FISH).
Trastuzumab was developed to target HER2: it's a recom-
binant, humanized IgG monoclonal antibody that selec-
tively binds with high affinity to the extracellular domain
of HER2 and inhibits the proliferation of tumour cells that
overexpress HER2. The underlying mechanism of the anti-
tumour effects of Trastuzumab has not been fully eluci-
dated, but it may involve a number of different actions
including: a) recruiting immune cells to target tumours
through antibody-dependent cellular cytotoxicity
(ADCC); b) inhibiting metalloproteinase-induced cleav-
age of the extracellular domain of HER2, thereby prevent-
ing the formation of a truncated HER2, which is thought
to have a role in the aggressiveness of breast tumours; c)
inhibiting HER2-mediated cellular proliferation that
depends on the signaling transduction pathways P13K/
Akt and MAPK, which are activated by HER-based dimers
and are essential for cellular proliferation and survival; d)
inhibiting HER2-mediated neo-angiogenesis.
Additive and/or synergistic effects have been demon-
strated with trastuzumab and various cytotoxic drugs
(paclitaxel, docetaxel, anthracyclines, cisplatin, carbopla-
tin, vinorelbine, capecitabine) in HER2-overexpressing
breast cancer cell lines and/or human breast xenograft
models. These evidences represent the rationale for the
concomitant use of this monoclonal antibody and chem-
otherapy.
The addition of intravenous trastuzumab to first-line
chemotherapy improved the time to disease progression,
objective response rate, duration of response, and overall
survival in randomized, multicentre trials in women with
HER2-positive metastatic breast cancer [1-11]. Thus, tras-
tuzumab has become the standard of care in this setting.Immunity & Ageing 2008, 5:16 http://www.immunityageing.com/content/5/1/16
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Recent data from large phase III trials with trastuzumab in
the adjuvant setting revealed significant improvements in
disease-free and overall survival: trastuzumab has also
become a component of adjuvant therapy for patients
with HER2-positive early breast cancer [12-16]. Trastuzu-
mab is under investigation in the neoadjuvant setting
[17,18].
The most common adverse events associated with trastu-
zumab are infusion-related symptoms, such as fever and
chills, usually occurring during the infusion of the first
dose; this drug is also associated with a number of serious
adverse events including cardiac events, severe hypersen-
sitivity reactions (including anaphylaxis) and pulmonary
events (infiltrates, pneumonia, fibrosis, pleural effusion,
acute pulmonary oedema). In particular, the risk of ven-
tricular dysfunction and congestive heart failure is partic-
ularly increased if trastuzumab is administered in
combination with anthracycline-containing chemother-
apy. The mechanism involved in trastuzumab-associated
cardiac events is different from that associated with
anthracycline: trastuzumab can activate HER2 receptor
tyrosine kinases in human myocardium, despite their low
level expression, resulting in cardiomyocyte disfunction.
Patients should undergo a cardiac assessment prior to
beginning trastuzumab therapy and cardiac function
should be monitored during trastuzumab therapy.
HER2 is also overexpressed in other malignancies, includ-
ing non-small cell lung cancer, gastric cancer, pancreatic
cancer, but trastuzumab, in these tumours, did not show
any clinical advantage.
Cetuximab is a human-mouse chimeric monoclonal anti-
body (IgG1 subtype) that binds to the extracellular
domain of EGFR/HER1 and block ligand binding and
receptor activation. Normally, after a ligand binds to a sin-
gle-chain EGFR, the receptor forms a dimer that signals
within the cell by activating receptor autophosphoryla-
tion through tyrosine kinase activity. Autophosphoryla-
tion triggers a series of intracellular pathways that may
result in cancer cell proliferation, blocking apoptosis, acti-
vating invasion and metastasis, and stimulating tumor-
induced neovascularization. This pathway is blocked by
anti-EGFR drugs.
EGFR is expressed in the majority of human epithelial
cancers and was the first growth factor receptor to be pro-
posed as a target for cancer therapy. EGFR expression is
usually determined by immunohistochemical methods
and was the first biomarker investigated as a potential pre-
dictor of response to anti-EGFR drugs: however, most
studies have failed to show any relationship between
EGFR expression and the clinical activity of these drugs.
Thus, in clinical practice Cetuximab is often administered
in patients affected by tumors that do not overexpress this
receptor.
A multicenter, randomized phase II trial evaluating the
activity of cetuximab alone or with irinotecan in patients
who did not respond to irinotecan therapy showed that
the combination was more effective in terms of response
rate and rate of progression-free survival, while the
median survival was similar with the two approaches [19].
Other studies have investigated the drug in association
with oxaliplatin +/- fluoropyrimidines (CRYSTAL,
EXPLORE, COIN, INT N0147) and with Bevacizumab
(20, CALGB 80405) in first and second line treatment for
metastatic disease.
On the basis of these results, cetuximab has been
approved in combination with irinotecan for the treat-
ment of metastatic colorectal cancer that is refractory to
irinotecan-based chemotherapy.
Cetuximab is also administered in combination with radi-
otherapy in patients with locally advanced squamous-cell
carcinoma of the head and neck: infact, in a randomized
phase III trial, radiotherapy and cetuximab significantly
prolonged progression-free survival, duration of locore-
gional control and overall survival [21]. Other trials are
investigating the drug in metastatic squamous-cell carci-
noma of the head and neck in combination with the
standard chemotherapy, cisplatin and fluorouracil
[22,23]. Cetuximab will be soon approved in other malig-
nancies, in particular NSCLC [24] and pancreatic cancer.
Dose-dependent and reversible diarrhea and acneiform
rashes have been the most prominent side effects, which
are very similar to those associated with the use of other
tyrosine kinase inhibitors: a significant positive correla-
tion between cutaneous toxicity and rates of response,
progression-free survival and overall survival has been
noted in virtually all trials.
Angiogenesis is a critical step in the growth and metastatic
spread of solid tumours: infact, in the absence of angio-
genesis, nascent tumors remain largely dormant, with a
maximum diameter of 100 to 200 μm, owing to limita-
tions in the diffusion of oxygen, glucose and waste prod-
ucts. Vascular endothelial growth factor (VEGF) has
emerged as a key mediator of tumor angiogenesis and has
recently been recognized as a potential target for therapy
of solid tumours. The VEGF family comprises glycopro-
teins designated VEGF-A, VEGF-B, VEGF-C, VEGF-D and
placental growth factor (PlGF): the best characterized of
the VEGF family members is VEGF-A, a homodimeric
glycoprotein that is expressed in four different isoforms
and binds to VEGFR1 and VEGFR2.Immunity & Ageing 2008, 5:16 http://www.immunityageing.com/content/5/1/16
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Bevacizumab derives from a murine monoclonal anti-
VEGF antibody, which is humanized (93% human) by
incorporating murine VEGF-binding residues into human
IgG framework. Bevacizumab causes inhibition of VEGF-
induced proliferation, migration and survival of vascular
endothelial cells and increases the permeability of these
cells by preventing the binding of soluble VEGF to its
receptors on the surface of endothelial cells. In addition to
its direct antiangiogenetic effects, bevacizumab may also
improve the delivery of chemotherapy by altering tumor
vasculature, decreasing the elevated interstitial pressure in
tumors and increasing the permeability of vascular
endothelium.
On the basis of the results of a randomized trial demon-
strating that the addition of bevacizumab to fluorouracil
and leucovorin+irinotecan results in statistically signifi-
cant and clinically meaningful improvement in survival
among patients with previously untreated metastatic
colorectal cancer [25], this drug has been approved for the
treatment of these patients.
Bevacizumab is also approved in association with oxalipl-
atin-based regimens for first line treatment of metastatic
colorectal cancer [26-28].
The drug has been approved for first line treatment of
metastatic breast cancer in combination with paclitaxel
[29], metastatic renal cancer in combination with inter-
feron [30], and will be soon used for the treatment of
NSCLC [31,32] and pancreatic cancer.
Potential side effects of bevacizumab include hyperten-
sion, proteinuria, bleeding and, infrequently, thrombotic
events: life threatening events have occurred in a small
number of patients.
The category of small molecules tyrosine kinase inhibitors
includes erlotinib, lapatinib, sunitinib and sorafenib, all
used in clinical practice.
Erlotinib is an oral EGFR tyrosine kinase inhibitor
recently approved for the treatment of locally advanced
and metastatic NSCLC patients who progress following 1
or 2 prior chemotherapy regimens. Its clinical use derives
from the results of a phase III, randomized, double blind,
placebo controlled study in which erlotinib increased
median survival by approximately 2 months as compared
with placebo. Response rates were significantly more fre-
quent in women, in patients with adenocarcinoma, and in
patients with no history of smoking: however, a signifi-
cant survival advantage was observed in all patient sub-
groups [33].
On the basis of preclinical data demonstrating that anti-
EGFR drugs potentiate the antitumor activity of cytotoxic
drugs, randomized trials have examined the combination
of erlotinib with chemotherapy as first-line treatment for
NSCLC: neither a survival advantage nor a benefit with
respect to the response rate or time to progression have
been seen with the addition of erlotinib to chemotherapy
in any of these trials [34,35].
Lapatinib is an oral ATP-competitive EGFR/HER1 and
HER2 dual tyrosine kinase inhibitor: it inhibits receptor
autophosphorylation and activation by binding to the
ATP-binding pocket of the EGFR/HER2. In patients with
HER2-positive advanced metastatic breast cancer that has
progressed following treatment with previous chemother-
apy regimens that included an anthracycline, a taxane,
and trastuzumab, a randomized clinical trial has demon-
strated that the addition of lapatinib to the chemotherapy
drug capecitabine delayed the time of further cancer
growth compared to capecitabine alone [36-38]. On the
basis of these results, lapatinib was approved in United
States in March 2007, for use in patients with advanced
metastatic breast cancer in conjunction with capecitabine:
it will be soon available in clinical practice also in our
country.
Sunitinib and sorafenib are two orally administered
multi-targeted tyrosine kinase inhibitors that have
recently been approved for the treatment of metastatic
renal-cell carcinoma (clear-cell histotype). Since renal-cell
carcinoma is highly resistant to chemotherapy, inter-
leukin-2 or interferon alfa were widely used as first line
treatment of metastatic disease. Response rate with these
cytokines were low (5 to 20%) and median overall sur-
vival was approximately 12 months. Alternative treat-
ments have been lacking for renal-cell carcinoma since the
development of these two innovative drugs.
Sunitinib inhibits tyrosine kinase associated with
VEGFR2, PDGFRβ, with less potent activity against fibrob-
last growth factor receptor 1 (FGFR1) tyrosine kinase; sor-
afenib is an inhibitor of Raf-1, a member of the RAF/MEK/
ERK signaling pathway, and of tyrosine kinase associated
to VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Flt-3 and c-KIT.
These receptor tyrosine kinases play a key role in the
pathogenesis of clear-cell carcinoma, through involve-
ment of the von Hippel-Lindau (VHL) gene, which is inac-
tivated in up to 80% of sporadic cases of clear-cell
carcinoma by deletion, mutation, or methylation. This
tumor-suppressor gene encodes a protein that is involved
in the regulation of the production of VEGF, PDGF and a
number of other hypoxia-inducible proteins: inactivation
of the VHL gene causes overexpression of these agonists of
VEGFR and PDGFR and the resulting persistent stimula-Immunity & Ageing 2008, 5:16 http://www.immunityageing.com/content/5/1/16
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tion of these receptors may promote tumor angiogenesis,
tumor growth and metastasis. This is the rationale for the
use of these small molecules in this tumor.
Sunitinib is approved for the first line treatment of meta-
static clear-cell renal carcinoma after the publication of
the results of a randomized phase III trial that has showed
a longer progression-free survival and higher response
rates, in the absence of survival benefit at the moment, in
patients who received this drug than in those receiving
interferon alfa [39]. Sunitinib is also approved for the sec-
ond line treatment of gastrointestinal stromal tumors
(GIST) [40] in progression after prior first line treatment
with Imatinib [41], a multitarget tyrosine kinase inhibitor
that principally blocks BCR-ABL kinase, c-kit and PDGFR-
associated kinases.
Sorafenib is approved for the second line treatment of
patients with metastatic clear-cell renal carcinoma in
whom previous standard therapy has failed; this indica-
tion in clinical setting derives from the results of a rand-
omized phase III trial that has showed longer progression-
free survival with sorafenib as compared with placebo
[42]. Sorafenib is also administered in patients with met-
astatic hepatocellular carcinoma [43], on the basis of the
results of a phase III, double blind, placebo-controlled
trial demonstrating that median survival and time to radi-
ologic progression were nearly 3 months longer for
patients treated with sorafenib than for those given pla-
cebo.
Both sunitinib and sorafenib are under investigation in
other malignancies (NSCLC, melanoma, breast cancer,
thyroid carcinoma, hormone-refractory prostate cancer,
etc).
The most common side effects associated with these drugs
are: fatigue, rash/desquamation, hand-foot skin reactions,
diarrhea, hypertension, anaemia, neutropenia, other car-
diac toxicities.
The drugs reported above represent only a part of the new
category of biological targeted agents: many novel drugs
are under investigation and will soon help oncologists in
the fight against cancer (e.g. other tyrosine kinase inhibi-
tors-ZD6474; other monoclonal antibodies-panitumu-
mab, matuzumab, pertuzumab; m-TOR inhibitors-
Temsirolimus, Everolimus; inhibitors of 26 S proteo-
some-bortezomib; histone deacetylase inhibitors-vorino-
stat; metalloproteinase inhibitors-marimastat, batimastat;
etc).
There is an increasing interest in the use of target therapies
in patients older than 65 years, which represent the fastest
growing segment of the cancer population. Concerns
about cancer treatment in the elderly relate to comorbidi-
ties, which increase proportionally with age, and physio-
logical changes associated with aging, which may
influence drug metabolism and toxicity. On the basis of
subgroups analysis, the major published clinical trials
suggest that administration of biological agents in this
class of patients is effective and safe. It would be worth-
while to design clinical trials having the elderly as target
population in order to better define the clinical use of
these drugs in this subset of patients.
Conclusion
Collaboration among laboratory scientists and clinical
scientists hold tremendous promise. Three of the main
future directions in the clinical use of target therapies are:
1) appropriate selection of patients who would benefit
from treatment with these new drugs by means of molec-
ular predictors of response; 2) determination of the most
effective sequence and combination of biological drugs to
use with chemotherapy, radiotherapy or both in order to
optimize cytotoxicity potentiation; 3) introduction of bio-
logical drugs in the adjuvant setting, on the basis of the
promising results obtained in the metastatic disease in
order to improve outcomes; 4) increasing need to include
the elderly population in clinical trials in order to define
the possible role of biological drugs in this category of
patients.
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